Nothing Special   »   [go: up one dir, main page]

CN1181019A - 含有贝那普利或贝那普利拉和维沙坦的药物组合物 - Google Patents

含有贝那普利或贝那普利拉和维沙坦的药物组合物 Download PDF

Info

Publication number
CN1181019A
CN1181019A CN96193111A CN96193111A CN1181019A CN 1181019 A CN1181019 A CN 1181019A CN 96193111 A CN96193111 A CN 96193111A CN 96193111 A CN96193111 A CN 96193111A CN 1181019 A CN1181019 A CN 1181019A
Authority
CN
China
Prior art keywords
milligrams
compositions
active component
valsartan
benazepril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96193111A
Other languages
English (en)
Chinese (zh)
Inventor
M·德加斯帕罗
R·L·维布
D·S·科恨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1181019A publication Critical patent/CN1181019A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN96193111A 1995-04-07 1996-04-02 含有贝那普利或贝那普利拉和维沙坦的药物组合物 Pending CN1181019A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH101295 1995-04-07
CH1012/95 1995-04-07

Publications (1)

Publication Number Publication Date
CN1181019A true CN1181019A (zh) 1998-05-06

Family

ID=4200393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96193111A Pending CN1181019A (zh) 1995-04-07 1996-04-02 含有贝那普利或贝那普利拉和维沙坦的药物组合物

Country Status (15)

Country Link
EP (1) EP0820302A1 (xx)
JP (1) JPH11503139A (xx)
KR (1) KR19980703647A (xx)
CN (1) CN1181019A (xx)
AU (1) AU5399096A (xx)
BR (1) BR9604818A (xx)
CA (1) CA2214143A1 (xx)
CZ (1) CZ313897A3 (xx)
HU (1) HUP9801593A2 (xx)
MX (1) MX9707683A (xx)
NO (1) NO974400D0 (xx)
PL (1) PL322529A1 (xx)
SK (1) SK133897A3 (xx)
TR (1) TR199701121T1 (xx)
WO (1) WO1996031234A1 (xx)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100377744C (zh) * 2002-07-05 2008-04-02 安徽省生物医学研究所 一种预测acei类降压药药效的复方药
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
CN105939728A (zh) * 2014-01-31 2016-09-14 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002032A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
WO2001076573A2 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
HU229280B1 (en) * 2000-07-19 2013-10-28 Novartis Ag Valsartan salts
EP1671632A1 (en) * 2000-08-22 2006-06-21 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
CN1461218A (zh) * 2000-12-18 2003-12-10 诺瓦提斯公司 阿洛地平和贝那普利的治疗组合
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003268219B2 (en) * 2002-08-28 2009-09-24 Barnes-Jewish Hospital Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
WO2010133638A1 (de) 2009-05-20 2010-11-25 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische telmisartan-trinklösung
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU653724B2 (en) * 1990-05-11 1994-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100377744C (zh) * 2002-07-05 2008-04-02 安徽省生物医学研究所 一种预测acei类降压药药效的复方药
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
CN105939728A (zh) * 2014-01-31 2016-09-14 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法
CN113144204A (zh) * 2014-01-31 2021-07-23 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法

Also Published As

Publication number Publication date
KR19980703647A (ko) 1998-12-05
NO974400L (no) 1997-09-23
NO974400D0 (no) 1997-09-23
EP0820302A1 (en) 1998-01-28
HUP9801593A2 (hu) 1999-01-28
SK133897A3 (en) 1998-02-04
JPH11503139A (ja) 1999-03-23
TR199701121T1 (xx) 1998-03-21
CZ313897A3 (cs) 1998-01-14
CA2214143A1 (en) 1996-10-10
BR9604818A (pt) 1998-06-09
WO1996031234A1 (en) 1996-10-10
PL322529A1 (en) 1998-02-02
AU5399096A (en) 1996-10-23
MX9707683A (es) 1997-12-31

Similar Documents

Publication Publication Date Title
RU2316318C2 (ru) Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
EP2322174B1 (en) Combined use of valsartan and calcium channel blockers for therapeutic purposes
RU2334513C2 (ru) Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
DE60202727T2 (de) Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie
CN1181019A (zh) 含有贝那普利或贝那普利拉和维沙坦的药物组合物
US6087386A (en) Composition of enalapril and losartan
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
US11123328B2 (en) Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
EP3132803B1 (en) Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
JP4609877B2 (ja) 慢性拒絶反応抑制剤
US6844361B2 (en) Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
HU206186B (en) Process for producing pharmaceutical compositions comprising amino acid derivatives having ace-inhibiting effect
Di Pasquale et al. Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction
KR20230161541A (ko) 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
RU2084225C1 (ru) Гипотензивное средство
EP1863492B1 (en) Use of megestrol acetate for improving heart function and the treatment of heart insufficiency
EA003470B1 (ru) Фармацевтическая композиция тгп и ингибитора апф
RU2261097C2 (ru) Применение моксонидина для лечения постинфарктных состояний
CN106267147A (zh) 一种复方降压药物组合物
JP2020176087A (ja) 骨パジェット病治療薬
Düsing et al. ALISKIREN PROVIDES MORE PROLONGED REDUCTIONS IN 24-HOUR MEAN AMBULATORY BLOOD PRESSURE DURING TREATMENT WITHDRAWAL THAN TELMISARTAN: PP. 15.393
WO2007023754A1 (ja) FBPase阻害剤を含有する薬剤
EP1710243A1 (en) Therapeutic agent for vasospasm accompanying bypass operation
Adam et al. O-33: Omapatrilat (OMA) a vasopeptidase inhibitor prevents mortality and cardiovascular injury in salt sensitive hypertension in addition to but independent of blood pressure
Zvyagintseva et al. NEW COMBINATION THERAPY FOR TREATMENT OF HYPERTENSION (EXPERIMENTAL STUDY): PP. 15.392

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication